BioGeneration and INKEF lead €4.8m round for Lanthio

MorphoSys (FSE:MOR) and Hanzepoort also contributed to the round.The funding round has held a first close but will remain open for another investor.

Lanthio has also signed a technology alliance agreement with MorphoSys to jointly develop Lanthio's drug discovery platform LanthioPep.

BioGeneration first invested in the company in 2011 to support its spinout from Groningen University.

Company
Lanthio Pharma is a Dutch pharmaceuticals company focused on developing lantipeptide drugs that show improved properties compared with traditional drugs, particularly with respect to degradation, initial activity and receptor specificity. It was founded in 2011, when it was spun out of Groningen University. 

People
Baart Wuurman is CEO of Lanthio.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Now researching
• Healthcare
• Early-stage
• Netherlands